相关实验视频

Updated: Feb 24, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

血GDF-15和PSP-D预测了系统性硬化症中肺动脉高血压的发展

Adam Engel Sällberg^1,2, Salaheldin Ahmed^1,2,3, Abdulla Ahmed^1,2,3

¹Department of Clinical Sciences Lund Cardiology, Lund University.

Pulmonary circulation

|February 23, 2026

概括

肺动脉高血压 (PAH) 的诊断往往会延迟. 这项研究确定了像GDF-15和PSP-D这样的炎症蛋白质,用于系统性硬化症 (SSc) 患者的PAH早期预测,以及IL-27和TNFRSF4用于PAH诊断和亚型分化.

科学领域:

生物化学生物化学
免疫学免疫学免疫学
肺部病理学肺部病理学

背景情况:

肺动脉高血压 (PAH) 存在诊断挑战,导致治疗延迟和不良结果.
确定用于早期检测和区分PAH亚型的生物标志物,包括异常 (IPAH/HPAH) 和与全身性硬化相关的PAH (SSc-APAH),至关重要.

研究的目的:

研究90种炎症和免疫调节蛋白在区分PAH亚型和预测PAH发展方面的诊断和预测价值.
通过多个患者队列验证这些蛋白质生物标志物.

主要方法:

用近距离延伸试验测量了血蛋白水平,用于PAH患者,健康对照组和全身性硬化症 (SSc) 患者的三个队列.
统计分析包括后勤回归,曲线下面积 (AUC) 计算和等效测试,以评估生物标志物的性能.

主要成果:

升高的IL-27水平将PAH患者与对照患者区分开来 (AUC=0.94).
TNFRSF4区分了SSc-APAH与IPAH/HPAH (AUC=0.82) 和对照组 (AUC=0.99) 的区别.
GDF-15和PSP-D预测了SSc患者在诊断前6年内发生PAH的发展 (AUC分别为0.78和0.73).

结论:

在SSc患者中,GDF-15和PSP-D作为早期查和预测PAH的生物标志物非常有希望.
IL-27和TNFRSF4是用于PAH诊断和SSc-APAH亚型区分的潜在生物标志物.

关键词:

生物标志物生物标志物检测检测检测检测检测一个多标志物小组.血蛋白质是血中的蛋白质.查检查查检查查检查查检查

更多相关视频

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

相关概念视频

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...